Azione 22UA BIONTECH SE
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue BioNTech SE BOERSE MUENCHEN

Azioni

22UA

US09075V1026

Mercato chiuso - BOERSE MUENCHEN
Altri mercati azionari
 21:59:55 14/06/2024 		Variaz. 5gg Var. 1 gen.
85,9 EUR -3,91% Grafico intraday di BioNTech SE -4,64% -6,03%
11/06 I titoli azionari europei scambiati negli Stati Uniti come ricevute di deposito americane sono in forte ribasso nelle contrattazioni del martedì MT
10/06 I titoli azionari europei scambiati negli Stati Uniti come ricevute americane di deposito sono scesi nelle contrattazioni del lunedì MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
BioNTech : ASCO 2024
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
Indonesia ramps up fight against tuberculosis amid concerns on economic impact
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
BioNTech : ASCO 2024
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading
GNW-Adhoc: Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione BNTX
  4. Azione 22UA
  5. Notizie BioNTech SE
  6. Altre lingue